BTAX: Biostax Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.75
Enterprise Value ($M) 3.92
Book Value ($M) -5.32
Book Value / Share -0.07
Price / Book -0.52
NCAV ($M) -5.33
NCAV / Share -0.07
Price / NCAV -0.52

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -246.16
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.00
Current Ratio 0.00

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.01
Liabilities 5.33
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-19 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment no. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UN
2024-07-05 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1
2024-05-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT U

(click for more detail)

Similar Companies
BSEM – BioStem Technologies, Inc. BSPK – Bespoke Extracts, Inc.
BSPM – Biostar Pharmaceuticals, Inc. BZYR – Burzynski Research Institute, Inc.
CALA – Calithera Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io